Elicio Therapeutics, Inc. (ELTX): Submission of Matters to a Vote of Security Holders
Elicio Therapeutics, Inc. (ELTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On November 12, 2026, Elicio Therapeutics, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders of the Company considered and voted on two
How this was made
The 30-second read
Why it matters
The filing confirms routine governance actions with no new strategic or financial announcements.
Market read
Minimal; the market likely already anticipated the governance vote.
What to watch
Potential future board composition changes, but not evident from this filing.
Background
Elicio Therapeutics filed an 8‑K detailing the results of its 2026 annual shareholder meeting, including election of three Class III directors and ratification of Baker Tilly US as auditor.
Ticker impact
SEC Form 8‑K reports the annual meeting vote on directors and auditor selection for Elicio Therapeutics.
neutral as the market has likely priced the governance outcomes.
The filing is a standard disclosure of shareholder votes; no material change to operations or capital structure.
Market effects
None; governance matters are company‑specific.
None
None
Counterpoint
Unlikely any short‑term price move; focus on longer‑term fundamentals.
Key entities
- companyElicio Therapeutics, Inc.
Biopharma company reporting its annual meeting outcomes.
- service_providerBaker Tilly US, LLP
Selected as the independent registered public accounting firm.
